Fredag 22 November | 10:26:34 Europe / Stockholm

Kalender

Tid*
2024-12-17 - Årsstämma
2024-11-30 - Bokslutskommuniké 2024
2024-11-12 - Extra Bolagsstämma 2024
2024-08-15 - Kvartalsrapport 2024-Q3
2024-05-30 - Årsstämma
2024-05-17 - Kvartalsrapport 2024-Q2
2024-03-01 - X-dag ordinarie utdelning CSMED 0.00 DKK
2024-02-14 - Bokslutskommuniké 2023
2024-02-14 - Kvartalsrapport 2024-Q1
2023-12-15 - X-dag ordinarie utdelning CSMED 0.00 DKK
2023-07-18 - Kvartalsrapport 2023-Q3
2023-05-17 - Kvartalsrapport 2023-Q2
2023-04-14 - Extra Bolagsstämma 2023
2023-02-17 - Kvartalsrapport 2023-Q1
2023-02-14 - Årsstämma
2023-02-10 - X-dag ordinarie utdelning CSMED 0.00 DKK
2022-11-18 - Bokslutskommuniké 2022
2022-08-13 - Kvartalsrapport 2022-Q3
2022-05-20 - Kvartalsrapport 2022-Q2
2022-02-18 - Kvartalsrapport 2022-Q1
2021-12-10 - X-dag ordinarie utdelning CSMED 0.00 DKK
2021-12-09 - Årsstämma
2021-11-18 - Bokslutskommuniké 2021

Beskrivning

LandDanmark
ListaSpotlight DK
SektorHälsovård
IndustriLäkemedel & Handel
CS Medica är ett danskt medicintekniskt bolag, dedikerat till läkemedelsforskning, utveckling, tillverkning och global kommersialisering. Bolaget blandar vetenskap och natur för att förbättra patienters liv med cannabinoidterapier för smärtlindring, och för att hantera autoimmuna och stressrelaterade symtom. Globalt erbjuder CS Medica CBD-behandlingar över disk (OTC), inklusive patenterade medicinska produkter, MHRA och MDR-registrerade artiklar, under varumärket CANNASEN® eller med egen märkning.
2024-07-31 11:10:13

CS MEDICA Approves Key Proposals at Extraordinary General Meeting

CS MEDICA ("CS MEDICA" or "The Company") is pleased to announce the successful approval of several key proposals at its Extraordinary General Meeting (EGM) held on July 31, 2024.  The approved resolutions are as follows:

1. Election of Chairman of the Meeting
  • Flemming Heegard was elected as the chairman of the meeting.
2. Capital Increase for Remuneration of IR Agreement
  • The shareholders approved a capital increase of 317,000 shares at DKK 3.00 per share, without pre-emption rights for existing shareholders.
  • The shares will be subscribed by Börsjakten AB or its related companies/persons, including its investor network.
  • These shares will be used to offset remuneration for an Investor Relations (IR) Agreement with Börsjakten AB, amounting to SEK 1,450,000.
  • The IR Agreement is set to run until July 11, 2025.
3. Cash Capital Increase
  • The shareholders approved a cash capital increase of 499,200 shares at DKK 3.00 per share, without pre-emption rights for existing shareholders.
  • The shares will be subscribed by Börsjakten AB or its related companies/persons, including its investor network.
4. Issuance of New Shares for IR-Related Activities
  • The shareholders approved the issuance of 3,000,000 new shares to CS MEDICA, with a nominal value of DKK 0.065 per share.
  • These shares will be used to secure payment for Investor Relations (IR) related activities.
  • The Company plans to engage various firms to enhance investor communication and engagement.
  • Remuneration for these IR-related services will be offset through the issuance of the proposed 3,000,000 shares, with the number of shares calculated monthly based on the invoices from the service providers, using the share price at the end of each month.

The total number of votes as of the date of this Statement is 12,322,635, of which 71.8%, equal to 8,842,160 votes, were represented at the EGM. The resolutions were approved unanimously by all shareholders represented at the EGM.